Provided by Tiger Trade Technology Pte. Ltd.

NEUROGENE INC

38.24
+0.36750.97%
Volume:117.97K
Turnover:4.47M
Market Cap:765.19M
PE:-7.58
High:39.72
Open:39.09
Low:36.86
Close:37.87
52wk High:43.66
52wk Low:15.93
Shares:20.01M
Float Shares:11.34M
Volume Ratio:1.04
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0440
EPS(LYR):-4.2400
ROE:-45.32%
ROA:-27.97%
PB:3.52
PE(LYR):-9.02

Loading ...

Neurogene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 05

Neurogene (NGNE) Receives a Buy from LifeSci Capital

TIPRANKS
·
Jul 11

Neurogene President, CFO Christine Mikail Cvijic Sells 4,800 Shares for $173,468.40

Reuters
·
Jul 08

Neurogene Grants Inducement Stock Options for 96,450 Shares to New Employees

Reuters
·
Jul 07

Neurogene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 07

Neurogene President, CFO Christine Mikail Cvijic Sells 4,800 Common Shares for $166,407.28

Reuters
·
Jul 03

Neurogene Says Cash Runway Extends into Q1 2029 After USD 134.8 Million Stock Offering

Reuters
·
Jul 02

U.S. Stocks on the Move-general Mills, Meta, Lockheed Martin

Reuters
·
Jul 01

Neurogene Prices USD 125 Million Follow-on Stock Offering at USD 30 Per Share

Reuters
·
Jul 01

Neurogene - Prices Public Offering of 3.5 Mln Shares at $30 Per Share

THOMSON REUTERS
·
Jul 01

Neurogene to Sell Shares in Secondary Offering

Dow Jones
·
Jul 01

Neurogene Inc: Files for Offering of Common Stock, Pre-funded Warrants to Buy Common Stock; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Jul 01

Neurogene Drops After Starting Equity Offering

Reuters
·
Jul 01

Neurogene announces common stock offering, no amount given

TIPRANKS
·
Jul 01

Neurogene Commences Public Offering of Common Stock, Pre-funded Warrants

Reuters
·
Jul 01

Neurogene Inc. Announces Proposed Public Offering

THOMSON REUTERS
·
Jul 01

Neurogene - Proceeds to Fund Ngn-401 Development, Pre-commercial Activities, and General Corporate Purposes

THOMSON REUTERS
·
Jul 01

Guggenheim Reaffirms Their Buy Rating on Neurogene (NGNE)

TIPRANKS
·
Jun 30

Analysts’ Top Healthcare Picks: ProQR (PRQR), Neurogene (NGNE)

TIPRANKS
·
Jun 29

Neurogene Says Ngn-401 Gene Therapy Shows Sustained Rett Syndrome Milestone Gains in Phase 1/2 Trial Through 30 Months

Reuters
·
Jun 29